Aller au contenu principal
2022 letter

Reply by Authors

0Citations signalées, ce qui n’est pas une note de qualité
3Institutions déclarées
1Pays d’affiliation déclarés

Rattachement africain : us. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

No AccessJournal of UrologyAdult Urology1 Dec 2022Reply by Authorsis a reply to letterEditorial Comment Bruce J. Trock, Yuezhou Jing, Brent Mabey, Zaina Sangale, Lauren Lenz, Nora Haney, Igor Vidal, Stephanie A. Glavaris, Gunes Guner, Onur Ertunc, Ibrahim Kulac, Javier A. Baena Del Valle, Tracy Jones, Misop Han, Alan W. Partin, Todd Cohen, Steven Stone, and Angelo M. De Marzo Bruce J. TrockBruce J. Trock *Correspondence: Department of Urology, Johns Hopkins School of Medicine, 600 N. Wolfe St., Park 211, Baltimore, Maryland 21287 telephone: 410-614-9440; email: E-mail Address: [email protected] James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, Maryland The Sidney Kimmel Comprehensive Cancer Institute at Johns Hopkins, Baltimore, Maryland More articles by this author , Yuezhou JingYuezhou Jing James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, Maryland More articles by this author , Brent MabeyBrent Mabey Myriad Genetics, Inc., Salt Lake City, Utah More articles by this author , Zaina SangaleZaina Sangale Myriad Genetics, Inc., Salt Lake City, Utah More articles by this author , Lauren LenzLauren Lenz Myriad Genetics, Inc., Salt Lake City, Utah More articles by this author , Nora HaneyNora Haney James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, Maryland More articles by this author , Igor VidalIgor Vidal Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland More articles by this author , Stephanie A. GlavarisStephanie A. Glavaris Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland More articles by this author , Gunes GunerGunes Guner Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland More articles by this author , Onur ErtuncOnur Ertunc Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland More articles by this author , Ibrahim KulacIbrahim Kulac Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland More articles by this author , Javier A. Baena Del ValleJavier A. Baena Del Valle Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland More articles by this author , Tracy JonesTracy Jones Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland More articles by this author , Misop HanMisop Han James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, Maryland More articles by this author , Alan W. PartinAlan W. Partin James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, Maryland The Sidney Kimmel Comprehensive Cancer Institute at Johns Hopkins, Baltimore, Maryland More articles by this author , Todd CohenTodd Cohen Myriad Genetics, Inc., Salt Lake City, Utah More articles by this author , Steven StoneSteven Stone Myriad Genetics, Inc., Salt Lake City, Utah Current affiliation: CareDx, Brisbane, California. More articles by this author , and Angelo M. De MarzoAngelo M. De Marzo James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, Maryland The Sidney Kimmel Comprehensive Cancer Institute at Johns Hopkins, Baltimore, Maryland Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002922.02AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail "Reply by Authors." The Journal of Urology, 208(6), pp. 1192–1193 References 1. Impact of the cell cycle progression test on physician and patient treatment selection for localized prostate cancer. J Urol. 2016; 195(3):612-618. Link, Google Scholar 2. Prognostic utility of biopsy-derived cell cycle progression score in patients with National Comprehensive Cancer Network low-risk prostate cancer undergoing radical prostatectomy: implications for treatment guidance. BJU Int. 2017; 120(6):808-814. Google Scholar © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsRelated articlesJournal of Urology1 Dec 2022Editorial Comment Volume 208Issue 6December 2022Page: 1192-1193 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Bruce J. Trock James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, Maryland The Sidney Kimmel Comprehensive Cancer Institute at Johns Hopkins, Baltimore, Maryland *Correspondence: Department of Urology, Johns Hopkins School of Medicine, 600 N. Wolfe St., Park 211, Baltimore, Maryland 21287 telephone: 410-614-9440; email: E-mail Address: [email protected] More articles by this author Yuezhou Jing James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, Maryland More articles by this author Brent Mabey Myriad Genetics, Inc., Salt Lake City, Utah More articles by this author Zaina Sangale Myriad Genetics, Inc., Salt Lake City, Utah More articles by this author Lauren Lenz Myriad Genetics, Inc., Salt Lake City, Utah More articles by this author Nora Haney James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, Maryland More articles by this author Igor Vidal Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland More articles by this author Stephanie A. Glavaris Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland More articles by this author Gunes Guner Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland More articles by this author Onur Ertunc Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland More articles by this author Ibrahim Kulac Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland More articles by this author Javier A. Baena Del Valle Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland More articles by this author Tracy Jones Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland More articles by this author Misop Han James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, Maryland More articles by this author Alan W. Partin James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, Maryland The Sidney Kimmel Comprehensive Cancer Institute at Johns Hopkins, Baltimore, Maryland More articles by this author Todd Cohen Myriad Genetics, Inc., Salt Lake City, Utah More articles by this author Steven Stone Myriad Genetics, Inc., Salt Lake City, Utah Current affiliation: CareDx, Brisbane, California. More articles by this author Angelo M. De Marzo James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, Maryland The Sidney Kimmel Comprehensive Cancer Institute at Johns Hopkins, Baltimore, Maryland Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland More articles by this author Expand All Advertisement PDF downloadLoading ...

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Reply by Authors
Date Crossref
01/12/2022
Éditeur
Ovid Technologies (Wolters Kluwer Health)
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Renal and related cancersPancreatic and Hepatic Oncology ResearchRenal cell carcinoma treatment

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.